From the ∗Department of Neuropsychiatry, Keio University School of Medicine, Tokyo
†Department of Psychiatry, Asaka Hospital, Fukushima
‡Department of Neuropsychiatry and Clinical Ethics, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan
§Geriatric Psychiatry Division, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
Received for publication June 25, 2018; accepted March 27, 2019.
Reprints: Hiroyuki Uchida, MD, PhD, Department of Neuropsychiatry, Keio University School of Medicine 35, Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan (e-mail: [email protected]).
T.T. and T.U. equally contributed to this work.
J.H. and H.U. equally contributed to this work.
T.T. has no conflict of interest or financial disclosures to report. T.U. has received grant from Novartis Pharma; speaker's honoraria from Mochida Pharmaceutical, Yoshitomi Pharmaceutical, and Meiji Pharmaceutical within the past 3 years. T.S. has received manuscript or speaker's fees from Astellas, Dainippon Sumitomo Pharma, Eli Lilly, Elsevier Japan, Janssen Pharmaceuticals, Meiji Seika Pharma, Novartis, Otsuka Pharmaceutical, Wiley Japan, and Yoshitomi Yakuhin, and research grants from Eisai, Mochida Pharmaceutical, and Meiji Seika Pharma. M.M. has received grants and/or speaker's honoraria from Asahi Kasei Pharma, Astellas Pharmaceutical, Daiichi Sankyo, Dainippon-Sumitomo Pharma, Eisai, Eli Lilly, Fuji Film RI Pharma, Janssen Pharmaceutical, Kracie, Meiji-Seika Pharma, Mochida Pharmaceutical, MSD, Novartis Pharma, Ono Yakuhin, Otsuka Pharmaceutical, Pfizer, Shionogi, Takeda Yakuhin, Tanabe Mitsubishi Pharma, and Yoshitomi Yakuhin within the past 3 years. J.H. has received grants from Pfizer Health Research Foundation within the past 3 years. H.U. has received grants from Eisai, Otsuka Pharmaceutical, Dainippon-Sumitomo Pharma, Mochida Pharmaceutical, Meiji-Seika Pharmaceutical, and Novartis; speaker's honoraria from Otsuka Pharmaceutical, Eli Lilly, Shionogi, Pfizer, Yoshitomi Yakuhin, Dainippon-Sumitomo Pharma, Meiji-Seika Pharma, MSD, and Janssen Pharmaceutical; and advisory panel payments from Dainippon-Sumitomo Pharma within the past 3 years.
Supplemental digital contents are available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s Web site (www.ectjournal.com).
